SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-030756
Filing Date
2022-08-24
Accepted
2022-08-24 16:41:01
Documents
14
Period of Report
2022-08-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20005031x2_8k.htm   iXBRL 8-K 43880
2 EXHIBIT 5.1 ny20005031x2_ex5-1.htm EX-5.1 6899
3 EXHIBIT 99.1 ny20005031x2_ex99-1.htm EX-99.1 19483
  Complete submission text file 0001140361-22-030756.txt   222575

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pdsb-20220824.xsd EX-101.SCH 3871
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pdsb-20220824_lab.xml EX-101.LAB 22546
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pdsb-20220824_pre.xml EX-101.PRE 16048
8 EXTRACTED XBRL INSTANCE DOCUMENT ny20005031x2_8k_htm.xml XML 4239
Mailing Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932
Business Address 25B VREELAND ROAD SUITE 300 FLORHAM PARK NJ 07932 800-208-3343
PDS Biotechnology Corp (Filer) CIK: 0001472091 (see all company filings)

IRS No.: 264231384 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37568 | Film No.: 221192014
SIC: 2834 Pharmaceutical Preparations